Nykode Therapeutics ASA Cash Flow-to-Debt Ratio
Nykode Therapeutics ASA cash flow-to-debt ratio. Nykode Therapeutics ASA (NYKD) has a Cash Flow-to-Debt Ratio of -1.11x as of June 2026, meaning its operating cash flow of Nkr-6.35 Million could theoretically repay -1% of its total liabilities (Nkr5.73 Million) in one year. Check NYKD operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Nykode Therapeutics ASA (2016–2025)
Cash flow-to-debt ratio of Nykode Therapeutics ASA from 2016 to 2025. Historical debt coverage capacity for Nykode Therapeutics ASA across 10 annual periods. Check Nykode Therapeutics ASA total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Nykode Therapeutics ASA Cash Flow-to-Debt Ratio by Year (2016–2025)
Nykode Therapeutics ASA cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Nykode Therapeutics ASA. For the full cash flow conversion analysis, see cash flow conversion of Nykode Therapeutics ASA.
| Year | CF-to-Debt Ratio | Operating CF (NOK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.50x | Nkr-29.46 Million | Nkr8.42 Million | ▼ -18.0% |
| 2024 | -2.97x | Nkr-51.22 Million | Nkr17.27 Million | ▼ -13.4% |
| 2023 | -2.62x | Nkr-96.62 Million | Nkr36.93 Million | ▼ -715.1% |
| 2022 | -0.32x | Nkr-20.69 Million | Nkr64.46 Million | ▼ -2087.3% |
| 2021 | 0.02x | Nkr1.16 Million | Nkr71.50 Million | ▼ -99.5% |
| 2020 | 3.52x | Nkr180.27 Million | Nkr51.18 Million | ▲ +293.3% |
| 2019 | -1.82x | Nkr-92.08 Million | Nkr50.52 Million | ▲ +61.5% |
| 2018 | -4.73x | Nkr-62.78 Million | Nkr13.27 Million | ▲ +17.6% |
| 2017 | -5.74x | Nkr-62.78 Million | Nkr10.94 Million | ▼ -525.2% |
| 2016 | -0.92x | Nkr-1.60 Million | Nkr1.74 Million | — |